>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

  • CHS +15.1%, FFIV +13.8%, NGL +12.3%, HOG +9.3%, CMI +9%, AB +8.7%, AFMD +7.1%, PI +6.7%, PKG +6.4%, KDP +6.2%, UBS +5.2%, ABB +4.9%, OMF +4.7%, SIRI +4.6%, DHI +4.5%, APY +4.1%, NXPI +4%, AMKR +4%, SSD +3.7%, MMM +3.2%, SPGI +3.1%, TAL +2.9%, MSCI +2.5%, FIX +2.4%, SC +2.4%, CGNX +2.3%, PII +2.2%, CNI +2%, PFE +2%, ARE +1.9%, PEP +1.9%, YNDX +1.7%, AVT +1.6%, LRN +1.5%, TCF +1.4%, BRO +1.4%, CAT +1.2%, CIGI +1.2%, PFG +1%, NVS +0.9%

Other news:

  • QTNT +31.8% (expects to complete CE marking process and the submission of the FDA EUA for the MosaiQ COVID-19 Antibody Microarray in the next few days)
  • SDC +18.4% (issued a patent for its SmileShop intellectual property from the United States Patent & Trademark Office)
  • RTIX +17.6% (revises terms of the sale of its OEM business to a private equity firm)
  • SNDX +17.3% (presents data for SNDX-5613 in adults with relapsed/refractory acute leukemias)
  • EGRX +16.1% (Eagle Pharma and Teva Pharmaceutical Industries (TEVA) announce patent decision in favor of Eagle and Teva for BENDEKA from the U.S. District Court for the District of Delaware)
  • OCUL +9.9% (announces top-line results of Phase 3 trial of DEXTENZA)
  • DGX +8.6% (to launch consumer-initiated COVID-19 testing through QuestDirect)
  • MRNA +8.5% (submits IND application to the FDA for the co's mRNA vaccine candidate (mRNA-1273) against SARS-CoV-2)
  • PCTY +7.7% (to join S&P MidCap 400)
  • ENPH +6.6% (to join S&P MidCap 400)
  • MFA +6.1% (enters into a second forbearance agreement with certain counterparties; provides additional company updates)
  • LH +4.2% (to offer COVID-19 antibody tests nationwide with no upfront out-of-pocket costs)
  • MDP +2.8% (to join S&P SmallCap 600)
  • AIR +2.6% (wins Air Force contact valued at $125 mln)
  • DAL +2.5% (raises $5 bln in debt, according to FT)
  • EQM +2.3% (lowers its quarterly distribution)
  • BLDP +2.2% (receives follow-on order from Solaris for 20 fuel cell modules to power buses in the Netherlands)
  • TEVA +1.7% (Eagle Pharma and Teva Pharmaceutical Industries Ltd. (TEVA) announce patent decision in favor of Eagle and Teva for BENDEKA from the U.S. District Court for the District of Delaware)

Analyst comments:

  • WPX +4.4% (upgraded to Buy from Neutral at Goldman)
  • BGS +2.3% (upgraded to Neutral from Underperform at Credit Suisse)